MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRTX849 acid
CAS :<p>MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.</p>Formule :C34H37ClFN7O4Couleur et forme :SolidMasse moléculaire :662.16KRAS inhibitor-34
CAS :<p>KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.</p>Formule :C43H41F3N6O3Couleur et forme :SolidMasse moléculaire :746.82KRASG12C IN-13
CAS :<p>KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.</p>Formule :C22H17ClF2N6OSCouleur et forme :SolidMasse moléculaire :486.93KRAS G12D inhibitor 11
CAS :<p>KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).</p>Formule :C29H38BN5O3Couleur et forme :SolidMasse moléculaire :515.4510-Methoxy-canthin-6-one
CAS :<p>10-Methoxy-canthin-6-one (Mtx-C) acts as a DNA damage inducer that embeds into DNA, promoting cell cycle arrest at the G2/M phase. This process triggers myeloid differentiation in acute myeloid leukemia cells (AML) and leukemia stem cells (LSC). Differentiation in AML and LSC cells is characterized by increased expression of myeloperoxidase, CD15, CD11b, and CD14, along with the activation of p38 MAPK. 10-Methoxy-canthin-6-one is utilized in the study of leukemia.</p>Formule :C15H10N2O2Couleur et forme :SolidMasse moléculaire :250.25KRAS G12C inhibitor 33
CAS :<p>KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.</p>Formule :C30H33N7O3Couleur et forme :SolidMasse moléculaire :539.63Refametinib R enantiomer
CAS :<p>Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used</p>Formule :C19H20F3IN2O5SDegré de pureté :99.86%Couleur et forme :SolidMasse moléculaire :572.34KRAS G12D inhibitor 9
CAS :<p>KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.</p>Formule :C33H43N7O2Couleur et forme :SolidMasse moléculaire :569.74JNK-1-IN-4
CAS :<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Formule :C22H25BrN6O3Couleur et forme :SolidMasse moléculaire :501.38LZTR1-KRAS modulator 1
CAS :<p>LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.</p>Formule :C11H11Cl2NOCouleur et forme :SolidMasse moléculaire :244.12KRAS inhibitor-32
CAS :<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Formule :C29H35FN10OS2Couleur et forme :SolidMasse moléculaire :622.78Anti-osteoporosis agent-11
CAS :<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Formule :C23H17NO2Se2Couleur et forme :SolidMasse moléculaire :497.31NDI-101150
CAS :<p>NDI-101150 (NMBS-2) is an HPK1 inhibitor with antitumor activity, inhibiting BLNK phosphorylation, and used in metastatic solid tumor research.</p>Formule :C27H27FN6O2Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :486.54INS018 055
CAS :<p>INS018 055 (TNIK&amp;MAP4K4-IN-2) is a TNIK and MAP4K4 inhibitor with anti-fibrotic activity.</p>Formule :C27H30FN7ODegré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :487.57Emprumapimod
CAS :<p>Emprumapimod, an oral p38α MAPK inhibitor, targets RPMI-8226 cells, curbs LPS-induced IL-6; IC50: 100 pM; for cardiomyopathy, acute pain.</p>Formule :C24H29F2N5O3Degré de pureté :99.21% - >99.99%Couleur et forme :SolidMasse moléculaire :473.52Rineterkib
CAS :<p>Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.</p>Formule :C26H27BrF3N5O2Degré de pureté :99.73%Couleur et forme :SolidMasse moléculaire :578.42CMK
CAS :<p>CMK, an RSK2 kinase inhibitor, shows similar potency but less chemical stability compared with FMK.</p>Formule :C18H19ClN4O2Couleur et forme :SolidMasse moléculaire :358.82Ravoxertinib hydrochloride
CAS :<p>Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).</p>Formule :C21H19Cl2FN6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :477.32Omtriptolide
CAS :<p>Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.</p>Formule :C24H28O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :460.479PLX7922
CAS :<p>PLX7922, a RAF inhibitor, demonstrates binding affinity with BRAF V600E and exhibits inhibitory effects on pERK in BRAF V600E cell lines, while inducing pERK activation in mutant NRAS cell lines.</p>Formule :C20H25FN6O2S2Couleur et forme :SolidMasse moléculaire :464.58
